Forest Cuts Combunox Detailing Following Disappointing Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.